Discovery of Biologic Therapeutics in the AI/ML Era

How can AI/Machine-Learning accelerate the discovery of new biomedical insights with high therapeutic application potential? View the full video interview here. This interview features Eddie Moler, the VP of Data Science at Juvenile Therapeutics, discussing the role of AI and machine learning in the discovery of biologic therapeutics. Moler explains his background in science and technology, transitioning from quantitative physical science to biology and life science applications. He highlights the impact of cloud technology and AI/ML in accelerating the discovery of new biological phenomena and developing therapies for various diseases. Juvenile Therapeutics, an early-stage biopharma startup, focuses on leveraging stem cell biology to identify and develop new treatments based on naturally secreted proteins. Moler discusses how AI and machine learning contribute to accelerating the discovery of biomedical insights with high therapeutic potential. He emphasizes the automation of drug discovery processes and the analysis of complex biological data, such as genomics and proteomics. Moler also mentions the challenge of examining hundreds of thousands of proteins and the role of AI in identifying key factors and patterns. He discusses the proprietary nature of technology and methods used but acknowledges the importance of sharing discoveries for scientific credibility. Moler concludes by highlighting the need for domain expertise and continuous learning in this rapidly evolving field.